Categories News Press Releases Archives 2025 June May April March February January 2024 December November October September August July June May April March February January 2023 December November October September August July June April March February January 2022 December November October September August June May March February January 2021 December November October September August May April February Mar 16 UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa Read More Share:| | | Jan 18 Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis Read More Share:| | | Jan 06 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review Read More Share:| | | Dec 23 UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab Read More Share:| | | Dec 09 UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa Read More Share:| | | Dec 07 The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis Read More Share:| | | Nov 22 UCB Submits Response to FDA Complete Response Letter for Bimekizumab Read More Share:| | | Nov 14 UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients Read More Share:| | | Nov 10 Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis Read More Share:| | | Nov 08 UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022 Read More Share:| | | Pagination First page Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Next page Next › Last page
